Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy
Year: 2006
Type: article
Study design: Clinical Trial
Source: Cancer
DOI: 10.1002/cncr.21834
Authors: Ken Wyman, Michael B. Atkins, Victor Prieto, Omar Eton, David F. McDermott, Francie Hubbard, Christine Byrnes, Kathleen Sanders, Jeffrey A. Sosman
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: National Cancer Institute
OpenAlex ID: W2015682571
